Chongqing Precision Biotechnology Co., Ltd, a Chinese biopharmaceutical company, has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for C-13-60 cell preparations as a local treatment in the abdominal cavity for CEA+ advanced malignant tumors, including a range of cancers such as colorectal, esophageal, gastric, pancreatic, non-small cell lung, breast, and bile duct. Additionally, MC-1-50 cell preparation has been granted clinical trial approval for the treatment of recurrent/refractory CD19 positive B-cell acute lymphoblastic leukemia.
Both product candidates are independently developed by Precision Biotechnology. C-13-60, derived from the company’s RESCAR and PHICAR platforms, is designed to enhance the aggregation of CAR cells to tumor sites, overcome immune suppression within the tumor microenvironment, and improve therapeutic efficacy while enhancing survival within the tumor environment. The product was first clinically approved in September of the previous year for the treatment of late-stage malignant solid tumors that have progressed or become intolerant to standard treatment with no effective alternatives available.
MC-1-50, developed through the PRIMCAR platform, has demonstrated superior efficacy and safety compared to conventionally prepared similar CAR-T products in the treatment of recurrent/refractory acute B-lymphocytic leukemia and recurrent/refractory B-cell non-Hodgkin lymphoma. It also shortens the Vein To Vein manufacturing process for the CAR-T product to one week.- Flcube.com
